

Serial No. 09/318,870
Atty. Docket No. 11111/1210

PRIORITY

E1

The present application claims priority under 35 U.S.C. §119(e) to U.S. Provisional Application Number 60/086,780, filed May 26, 1998, the entirety of which is incorporated herein by reference.

In the Claims

✓ ✓ ✓ ✓ ✓
Please **cancel** claims 9-12, 15-16, and 21.

Please **replace** claims 1, 2, and 13 with the following claims.

E2

1. A method of vaccinating a mammal to a selected antigen, the method comprising

administering to a mammal a vaccine composition comprising a cytokine-coated cell comprising said selected antigen, wherein said cytokine of said cytokine-coated cell is exogenous to said cell, and wherein said mammal is vaccinated to said selected antigen.

2. A method of vaccinating a mammal to a selected antigen, the method comprising

E3

administering to a mammal a vaccine composition comprising a cytokine-coated cell, , wherein said cytokine of said cytokine-coated cell is exogenous to said cell, wherein said cytokine-coated cell comprises said selected antigen and is admixed with an engineered cytokine, and wherein said mammal is vaccinated to said selected antigen.

E4

13. A method of vaccinating a mammal to a selected antigen, the method comprising administering to the mammal a vaccine composition comprising a cytokine-coated cell, , wherein said cytokine of said cytokine-coated cell is exogenous to said cell, wherein said cytokine is a ligand for the GM-CSF receptor, and wherein said mammal is vaccinated to said selected antigen.

REMARKS

Pending Claims

Claims 1-25 are pending. Claims 9-12, 15-16, and 21 are canceled, and claims 1, 2 and 13 are amended. Upon entry of this Amendment and Response, claims 1-8, 13-14, 17-20, and 22-25 are presented for examination. No new matter is added by this amendment. Support for